Congress and the Department of Justice now join the inquiry about the FDA actions investigating the alleged falsification of test records. This is where joint committees could also stand to shed some light here as both Australia and the UK are working with the FDA in reference to drug factories in China and India. As the Congressional investigation continues this certainly sets a real precedence to keep active inspections alive and going at all times as it stands to endanger the safety of lives with those taking the generic drugs.
I certainly hope this is not the case, but the “economic decisions” of what 
happened in China with the Heparin scandal still remain fresh in my mind and I’m sure others may render the same feelings when it comes to drug safety. BD
NEW YORK: The US drug regulator FDA, which has charged Ranbaxy with selling unsafe medicines in the country, has come under the Congress scanner and will be probed for its conduct in approving the Indian pharma major's products and other potential violations in the matter. A Congressional Committee has said that it would examine Ranbaxy's drug approvals in the US and potential violations of manufacturing regulations, a media report said. Besides, the House Energy and Commerce Committee would also "look at why the FDA continued to approve medicines made by the company and allow shipments into the US while it was questioning Ranbaxy's manufacturing processes," the Star Ledger newspaper reported.
FDA comes under Congress scanner over Ranbaxy issue- Policy-Economy-News-The Economic Times
0 comments :
Post a Comment